GSK loses out to Pfizer in supplying domestic market with RSV vaccine

24 Jun 2024
firstwordpharma.com
VaccineDrug ApprovalClinical Study
GSK lost out to a key rival in the battle to supply respiratory syncytial virus (RSV) vaccines for the UK’s upcoming immunisation programme, dealing a blow to the drugmaker on its home turf. In documents published Monday, the UK Health Security Agency said that Pfizer’s RSV shot Abrysvo has been chosen ahead of GSK’s Arexvy.
The UK’s immunisation programme will kick off at the start of September, targeting adults aged between 75 years and 79 years, as well as pregnant women to protect their infants. The Health Security Agency noted that Abrysvo will be used in both groups.
Pfizer’s shot is approved for use in the two groups, while GSK’s jab is only authorised for use in older adults. The two products carry list prices of $295 and $280, respectively, in the US, although discounts are typically offered to government tenders, such as for the UK’s programme.
According to Bloomberg – citing the contents of a redacted contract published earlier this month – Pfizer will supply over 3.5 million doses of Abrysvo for older adults and more than 1.4 million doses to pregnant mothers in England and Northern Ireland over the next two years. While further details were not disclosed, a Pfizer spokesperson said that the contract followed a competitive tender process.
GSK’s vaccine has so far been leading the sales battle of the RSV vaccines, bringing in revenue of £1.2 billion ($1.5 billion) last year, compared with $890 million for Pfizer’s shot.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.